Who founded Prolocor?

Prolocor was founded by Peter M. DiBattiste, David J. Schneider in 2020.

Who are Prolocor's investors?

Prolocor's investors include at Hula, Green Park & Golf Ventures.

How much funding has Prolocor raised?

Prolocor has disclosed $1.6M raised across 1 of its 3 known rounds.

Where is Prolocor headquartered?

Prolocor is headquartered in Philadelphia, US.

Prolocor

Philadelphia, US · Founded 2020 · Delaware corporation · 3 known investors

Find your way into Prolocor

Paths you didn't know you had: your email and LinkedIn already hold routes to the Prolocor team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Prolocor was founded in 2020 by Peter M. DiBattiste and David J. Schneider.

Peter M. DiBattisteCo-founder · President and CEO

David J. SchneiderCo-founder & CSO

Investors · 3

at Hulalisted by at HulaBurlington

Green Park & Golf Ventureslisted by Green Park & Golf VenturesDallas · $500K – $2M

How we know: Green Park & Golf Ventures's portfolio page · globenewswire.com · Not right? Tell us

Also in the syndicate · 1

Labcorp

Funding

SEC filings, press & company announcements

$1.6M disclosed across 1 of 3 rounds · 2021–2024

Undisclosed amountBridgeMar 2024
Source ↗
Undisclosed amountseed roundAug 2022
Green Park & Golf Ventures (lead), Labcorp
Source ↗

▶$1.6MraisedJan 2022 · 11 investors · Biotechnology

Officers, directors & promoters on the filing

Peter M. DiBattisteExecutive Officer, Director
David SchneiderExecutive Officer, Director

Offering amount: $3M
Amount sold: $1.6M
First sale: Jul 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 04.3

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Capricor TherapeuticsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.

AliveCorAliveCor develops digital health solutions focused on cardiovascular care, serving employers and healthcare payers seeking enterprise heart health platforms.

Companies working in the same space as Prolocor.

Frequently asked questions

What does Prolocor do?: Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.
Who founded Prolocor?: Prolocor was founded by Peter M. DiBattiste, David J. Schneider in 2020.
Who are Prolocor's investors?: Prolocor's investors include at Hula, Green Park & Golf Ventures.
How much funding has Prolocor raised?: Prolocor has disclosed $1.6M raised across 1 of its 3 known rounds.
Where is Prolocor headquartered?: Prolocor is headquartered in Philadelphia, US.